Susquehanna International Group
AKTX

Susquehanna International Group’s Akari Therapeutics AKTX Stock Holding History

Susquehanna International Group’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-431
Closed -$48.1K – 11875
2024
Q2 		$48.1K Buy
+431
New +$31.8K ﹤0.01% 11428
2019
Q2 		– Sell
-27
Closed -$77K – 10155
2019
Q1 		$77K Sell
27
-8
-23% -$15.3K ﹤0.01% 8344
2018
Q4 		$43K Buy
+35
New +$51.3K ﹤0.01% 8528

Other funds holding AKTX

OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CPG
Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return

Susquehanna International Group's AKTX Position: Q3 2024 in Review

Susquehanna International Group sold out of Akari Therapeutics (AKTX) in Q3 2024, closing a stake of 431 shares — an estimated $48.1K sold.

Susquehanna International Group first reported a position in AKTX in Q4 2018 and held it in 3 quarters. The position peaked at $77K in Q1 2019. 8 funds tracked by Wall St. Rank hold AKTX as of Q3 2024.

  • Susquehanna International Group reported no remaining Akari Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Susquehanna International Group sold 431 Akari Therapeutics shares in Q3 2024, an estimated $48.1K.
  • Susquehanna International Group first reported a position in Akari Therapeutics in Q4 2018 and held it in 3 quarters.
  • Susquehanna International Group's Akari Therapeutics position peaked at $77K in Q1 2019.
  • 8 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.